Literature DB >> 20353360

Evaluation of International Classification of Diseases, Ninth Revision, Clinical Modification Codes for reporting methicillin-resistant Staphylococcus aureus infections at a hospital in Illinois.

Melissa K Schaefer1, Katherine Ellingson, Craig Conover, Alicia E Genisca, Donna Currie, Tina Esposito, Laura Panttila, Peter Ruestow, Karen Martin, Diane Cronin, Michael Costello, Stephen Sokalski, Scott Fridkin, Arjun Srinivasan.   

Abstract

BACKGROUND: States, including Illinois, have passed legislation mandating the use of International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes for reporting healthcare-associated infections, such as methicillin-resistant Staphylococcus aureus (MRSA).
OBJECTIVE: To evaluate the sensitivity of ICD-9-CM code combinations for detection of MRSA infection and to understand implications for reporting.
METHODS: We reviewed discharge and microbiology databases from July through August of 2005, 2006, and 2007 for ICD-9-CM codes or microbiology results suggesting MRSA infection at a tertiary care hospital near Chicago, Illinois. Medical records were reviewed to confirm MRSA infection. Time from admission to first positive MRSA culture result was evaluated to identify hospital-onset MRSA (HO-MRSA) infections. The sensitivity of MRSA code combinations for detecting confirmed MRSA infections was calculated using all codes present in the discharge record (up to 15); the effect of reviewing only 9 diagnosis codes, the number reported to the Centers for Medicare and Medicaid Services, was also evaluated. The sensitivity of the combination of diagnosis codes for detection of HO-MRSA infections was compared with that for community-onset MRSA (CO-MRSA) infections.
RESULTS: We identified 571 potential MRSA infections with the use of screening criteria; 403 (71%) were confirmed MRSA infections, of which 61 (15%) were classified as HO-MRSA. The sensitivity of MRSA code combinations was 59% for all confirmed MRSA infections when 15 diagnoses were reviewed compared with 31% if only 9 diagnoses were reviewed (P < .001). The sensitivity of code combinations was 33% for HO-MRSA infections compared with 62% for CO-MRSA infections (P < .001).
CONCLUSIONS: Limiting analysis to 9 diagnosis codes resulted in low sensitivity. Furthermore, code combinations were better at revealing CO-MRSA infections than HO-MRSA infections. These limitations could compromise the validity of ICD-9-CM codes for interfacility comparisons and for reporting of healthcare-associated MRSA infections.

Entities:  

Mesh:

Year:  2010        PMID: 20353360     DOI: 10.1086/651665

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  17 in total

1.  Swine exposure and methicillin-resistant Staphylococcus aureus infection among hospitalized patients with skin and soft tissue infections in Illinois: A ZIP code-level analysis.

Authors:  Glennon A Beresin; J Michael Wright; Glenn E Rice; Jyotsna S Jagai
Journal:  Environ Res       Date:  2017-07-31       Impact factor: 6.498

2.  Changing epidemiology of methicillin-resistant Staphylococcus aureus in the Veterans Affairs Healthcare System, 2002-2009.

Authors:  A R Caffrey; K L LaPlante
Journal:  Infection       Date:  2011-12-13       Impact factor: 3.553

3.  Assessing diagnostic coding practices among a sample of healthcare facilities in Lyme disease endemic areas: Maryland and New York - A Brief Report.

Authors:  N Thomas; H J Rutz; S A Hook; A F Hinckley; G Lukacik; B P Backenson; K A Feldman; J L White
Journal:  Zoonoses Public Health       Date:  2017-10-30       Impact factor: 2.702

4.  Validity and Reliability of Administrative Coded Data for the Identification of Hospital-Acquired Infections: An Updated Systematic Review with Meta-Analysis and Meta-Regression Analysis.

Authors:  Olga Redondo-González; José María Tenías; Ángel Arias; Alfredo J Lucendo
Journal:  Health Serv Res       Date:  2017-04-11       Impact factor: 3.402

5.  Trends in methicillin-resistant Staphylococcus aureus bloodstream infections using statewide population-based surveillance and hospital discharge data, Connecticut, 2010-2018.

Authors:  Ashley N Rose; Paula Clogher; Kelly M Hatfield; Runa H Gokhale; Isaac See; Susan Petit
Journal:  Infect Control Hosp Epidemiol       Date:  2020-06       Impact factor: 3.254

6.  Association of Evidence-Based Care Processes With Mortality in Staphylococcus aureus Bacteremia at Veterans Health Administration Hospitals, 2003-2014.

Authors:  Michihiko Goto; Marin L Schweizer; Mary S Vaughan-Sarrazin; Eli N Perencevich; Daniel J Livorsi; Daniel J Diekema; Kelly K Richardson; Brice F Beck; Bruce Alexander; Michael E Ohl
Journal:  JAMA Intern Med       Date:  2017-10-01       Impact factor: 21.873

7.  Validity of ICD-9-CM coding for identifying incident methicillin-resistant Staphylococcus aureus (MRSA) infections: is MRSA infection coded as a chronic disease?

Authors:  Marin L Schweizer; Michael R Eber; Ramanan Laxminarayan; Jon P Furuno; Kyle J Popovich; Bala Hota; Michael A Rubin; Eli N Perencevich
Journal:  Infect Control Hosp Epidemiol       Date:  2011-02       Impact factor: 3.254

8.  Increasing burden of methicillin-resistant Staphylococcus aureus hospitalizations at US academic medical centers, 2003-2008.

Authors:  Michael Z David; Sofia Medvedev; Samuel F Hohmann; Bernard Ewigman; Robert S Daum
Journal:  Infect Control Hosp Epidemiol       Date:  2012-06-11       Impact factor: 3.254

9.  Reduction of methicillin-resistant Staphylococcus aureus infection among veterans in Atlanta.

Authors:  Edward Stenehjem; Cortney Stafford; David Rimland
Journal:  Infect Control Hosp Epidemiol       Date:  2012-11-14       Impact factor: 3.254

10.  Use of the International Classification of Diseases, 9th revision, coding in identifying chronic hepatitis B virus infection in health system data: implications for national surveillance.

Authors:  Reena Mahajan; Anne C Moorman; Stephen J Liu; Loralee Rupp; R Monina Klevens
Journal:  J Am Med Inform Assoc       Date:  2013-03-05       Impact factor: 4.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.